ABSTRACT. It is known that topoisomerase II= = = = is phosphorylated by several kinases. To elucidate the role of phosphorylation of topoisomerase II= = = = in the cell cycle, we have examined the cell cycle behavior of phosphorylated topoisomerase II= = = = in HeLa cells using antibodies against several phospho-oligopeptides of this enzyme. Here we demonstrate that serine1212 in topoisomerase II= = = = is phosphorylated only in the mitotic phase. Using an antibody against an oligopeptide containing phosphoserine-1212 in topoisomerase II= = = = (PS1212), subcellular localization of topoisomerase II= = = = phosphorylated at serine1212 was examined by indirect immunofluorescence staining, and compared with that of overall topoisomerase II= = = =. Serine1212-phosphorylated topoisomerase II= = = = was localized specifically on mitotic chromosomes, but not on interphase chromosomes; this result contrasts with overall topoisomerase II= = = = which was observed on chomosomes in both interphase and mitosis. Serine1212-phosphorylated topoisomerase II= = = = first appeared on chromosome arms in prophase, became concentrated on the centromeres in metaphase, and disappeared in early telophase. In addition, ICRF-193, a catalytic inhibitor of topoisomerase II, prevented accumulation of serine1212-phosphorylated topoisomerase II= = = = at the centromeres. These results indicate that serine1212 of topoisomerase II= = = = is phosphorylated specifically during mitosis, and suggest that the serine1212-phosphorylated topoisomerase II= = = = acts on resolving topological constraint progressively from the chromosome arm to the centromere during metaphase chromosome condensation.
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Key words: topoisomerase/phosphorylation/centromere/mitosis/HeLa cells/fluorescence microscopy DNA topoisomerases are essential enzymes involved in various DNA metabolism and chromosome dynamics throughout the cell cycle by catalyzing topological changes in DNA (Cozzarelli and Wang, 1990; Wang, 1996) . There are two types of DNA topoisomerases, topoisomerases I and II, which catalyze topological changes in DNA by transiently introducing single-and double-strand breaks, respectively. While both topoisomerases I and II relax supercoiled DNA, only topoisomerase II can catalyze knotting/unknotting and catenation/decatenation. Due to this unique catalytic activity, topoisomerase II plays a role in chromosome condensation and segregation in the mitotic phase (DiNardo et al., 1984; Uemura and Yanagida, 1986; Adachi et al., 1991; Ishida et al., 1994) . In addition to the biological role through its catalytic activity, topoisomerase II may function to anchor chromosomal DNA loops to the chromosome scaffold Gasser et al., 1986) , although the structure of the chromosome scaffold was not disrupted by the removal of topoisomerase II from the condensed chromosomes reconstituted in mitotic Xenopus oocyte extracts (Hirano and Mitchison, 1993) . In the mitotic phase of the cell cycle, topoisomerase II redistributes from the chromosome scaffold to the centromeres in mammalian cells Rattner et al., 1996; Sumner, 1996) .
Protein levels of topoisomerase II dramatically increase when the cell moves from the stationary to the growing phase (Duguet et al., 1983; Heck and Earnshaw, 1986; Hsiang et al., 1988) . On the other hand, its protein levels re-main relatively constant during the cell cycle, and the activity is presumed to be modulated at post-translational levels such as phosphorylation; in mammalian cells, for instance, phosphorylation of topoisomerase II increases during the S and G2/M phases (Estey et al., 1987) and the phosphorylation sites change in the cell cycle. Furthermore, MPM-2 antibody (Davis et al., 1983) , which recognizes mitotic phosphoproteins, reacts with topoisomerase II (Taagepera et al., 1993; Escargueil et al., 2000) . From these observations, it has been inferred that phosphorylation is associated with mitotic functions of topoisomerase II.
Phosphorylation of topoisomerase II has been demonstrated in vitro by various protein kinases such as cdc2 kinase, casein kinase II, protein kinase C, and Ca 2+ calmodulin-dependent protein kinase (Ackerman et al., 1985; Sahyoun et al., 1986; Rottmann et al., 1987; Heck et al., 1989; Daum and Gorbsky, 1998) . In Drosophila and budding yeast, the major in vivo phosphorylation sites of topoisomerase II correspond to those of casein kinase II in vitro (Ackerman et al., 1988; Cardenas et al., 1992; Daum and Gorbsky, 1998) , and topoisomerase II is copurified with casein kinase II from budding yeast and from Drosophila (Cardenas et al., 1992; Bojanowski et al., 1993) . Involvement of MAP kinase and protein kinase C in phosphorylation of topoisomerase II has also been reported in human cultured cells . The phosphorylated sites of yeast and mammalian topoisomerase II are concentrated at the C-terminal region, although some phosphorylation has been noted also in the N-terminal domain of the enzyme (Cardenas et al., 1992; Shiozaki and Yanagida, 1992; . The C-terminal region of the enzyme does not contain a catalytic function domain, and is speculated to be involved in the negative regulatory function of enzyme activity or in interaction with other proteins (Watt et al., 1995; Wang et al., 1996) .
Two isoforms of topoisomerase II, = and >, are present in mammalian cells, and both are phosphorylated Ishida et al., 1996; Kimura et al., 1996) . The two types of topoisomerase II are mapped to different genes (Tan et al., 1992) , and have distinct characteristic in molecular masses, biochemical properties and susceptibilities to various topoisomerase II inhibitors (Drake et al., 1989) . In mitosis, topoisomerase II= binds to chromatin while topoisomerase II> is located in cytosol. Moreover, it has been shown that cell lines lacking topoisomerase II> are viable (Chen and Beck, 1995; Dereuddre et al., 1997; Grue et al., 1998) although it is necessary during neuronal development (Yang et al., 2000) . Thus, topoisomerase II=, but not II>, plays an essential role in cell proliferation and mitotic chromosome condensation and segregation.
The activity of topoisomerase II= may be modulated by phosphorylation and/or localization. To examine phosphorylation and subcellular localization of topoisomerase II= during the cell cycle, we prepared antibodies against various phospho-oligopeptides of topoisomerase II= (Ishida et al., 1996) . In the previous study, using the antibody against phosphorylated threonine-1342 of topoisomerase II=, we showed that the site is phosphorylated in vivo throughout the cell cycle (Ishida et al., 1996) . In this study, we examined phosphorylation of topoisomerase II= at serine1212, using an antibody raised against oligopeptides containing serine1212 and neighboring peptides corresponding to the residues 1204-1219 in human topoisomerase II= as this oligopeptide sequence contains cdc2 or the MAP kinase recognition motif (Kemp and Pearson, 1990 ). Here we demonstrate that serine1212 is phosphorylated only in mitosis. Moreover, phosphorylated topoisomerase II= relocalizes from chromosome arms to the centromere, and the relocalization is inhibited by an inhibitor of the enzyme activity. These results suggest that phosphorylated topoisomerase II= moves along the chromosome toward the centromere while resolving topological constraint of chromosomes during metaphase chromosome condensation.
Materials and Methods

Peptides
Phosphorylated oligopeptides in human topoisomerase IIa, TQ-MAEVLP-S(PO3)-PRGQRVI (designated PS1212), EDAKKRL-S(PO3)-VERIYQKK (designated PS29), PMLNGTEK-T(PO3)-PPLITDY (designated PT949), ELDTLKRK-S(PO3)-PSDLWK (designated PS1161) and FSDFDEK-T(PO3)-DDEDFVPC (designated PT1342), were synthesized as described previously (Wakamiya et al., 1997) and the non-phosphorylated oligopeptide, S1212, were purchased from Peptide Institute, Inc., or from Kurabo Co., both in Osaka, Japan.
Antibodies
Anti-PS1212 antibody was prepared as described previously (Ishida et al., 1996) . In brief, PS1212-KLH emulsified in complete Freund's adjuvant was injected intraperitoneally into Balb/c mice. A booster of the PS1212-KLH emulsion was given to the mice at 2-week intervals. The hybridoma cells producing anti-PS1212 antibody were grown as ascites tumors in BALB/c mice primed with pristane. A homogeneous IgG fraction was prepared by applying ascites fluid to protein A-gel (Bio-Rad) and following elution. Anti-PT1342 mouse monoclonal antibody was raised against a phosphorylated synthetic peptide, FSDFDEK-T(PO3)-DDED-FVPC, in human topoisomerase IIa (Ishida et al., 1996) . Antitopoisomerase II mouse monoclonal antibodies (4E12 and 1C5) were raised against human topoisomerase II purified from HL60 cells; these antibodies specifically recognize topoisomerase IIa (Ishida et al., 1996) . The anti-a-tubulin rat monoclonal antibody, YOL1/34, was purchased from Sera-Lab (Sussex, England), and the human autoimmune antibody, SA, which reacts with human centromere proteins, CENP-A, B and C, was a gift from Dr. H. Masumoto (Nagoya University, Nagoya, Japan).
Cell lysis
Exponential-phase HeLa cells were pelleted at 1,000 rpm for 5 min at 4°C, and lysed on ice for 1h by resuspension in cold lysis buffer [50mM Tris-HCl buffer, 350mM NaCl, 0.1%(v/v) Nonidet P-40, 5 mM Na2EDTA, 50 mM NaF, PH 7.4] containing protease inhibitors (2mM phenylmethane sulphonyl fluoride and 20 mg/ml each of antipain, aprotinin, chymostatin, leupeptin and pepstatin A) and then centrifuged at 14,000 rpm for 10 min at 4°C. The resulting supernatants were used for immunoprecipitation. For immunoblotting, the supernatants were used after boiling for 5 min in SDS/ PAGE loading buffer.
Immunoprecipitation and immunoblotting
Topoisomerase IIa was immunoprecipitated from whole cell lysates by using 1 ml of anti-topoisomerase II antibody (1C5) per 50 mg of lysate protein. The lysate/antiserum mixture was incubated at 4°C for 1h. Twenty ml of 50 % suspension of protein G sepharose was then added and the mixture was shaken at 4°C for 1h. Protein-G sepharose-topoisomerase II complexes were pelleted at 1,000 rpm for 5 min at 4°C and washed three times with 500 ml of cold lysis buffer containing the protease inhibitors. The immunoprecipitates were resuspended in 30 ml of SDS polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer (62.5 mM TrisHCl, pH 6.8, 12.5% glycerol, 1.25% SDS, 1.25% 2-mercaptoethanol) and boiled for 5 min. After centrifugation at 1,000 rpm for 5 min, the resulting supernatant was subjected to SDS-PAGE on 7.5% polyacrylamide gel and blotted onto a PVDF membrane. The blots were incubated with various antibodies for 1 h and subsequently with HRP-conjugated anti-mouse IgG serum (Amersham) for 1 h and detected by enhanced chemiluminescence (ECL) using the ECL western-blot detection system (Amersham International, Little Chalfont, UK).
Synchronization
To synchronize cells in the S phase, 1´10 6 HeLa cells were cultured for 20 h in the presence of 1 mM thymidine, and for 9 h in the absence of the nucleotide, and finally for 16 h in the presence of 1 mM thymidine; after removal of the thymidine, the cells were allowed to progress to the S phase. For M phase synchronization, HeLa cells were synchronized as described previously .
Flow cytometry
Cells were trypsinized, washed with phosphate buffered saline (PBS) and fixed in 70% methanol at -20°C for 1 h or longer. The fixed cells were then pelleted and washed with PBS. After being washed with PBS containing 0.1% Triton-X100, the cells were resuspended with 100 ml of PBS containing RNase A (0.5 mg/ml), and incubated for 10 min, followed by the addition of propidium iodide (PI, 10 mg/ml). After the cells had been passed through nylon mesh, flow cytometry was performed on FACScan (BectonDickinson).
Indirect immunofluorescence microscopy
HeLa cells were cultured in a glass-bottom culture dish (MatTek Corp., Ashland, MA, USA). For indirect immunofluorescence staining, cells were fixed with 100% methanol at -30°C for 30 min, washed three times with PBS and incubated in a blocking buffer, 1% BSA in PBS, for at least 1 h at room temperature. The cells were then incubated with antibody against topoisomerase II (1:100-500 dilution), alpha-tubulin (1:500 dilution) or human centromere proteins (1:100 dilution) for 20 h at 4°C, again washed three times with PBS, and incubated with fluorescence-labelled antibodies, Cy-2-conjugated anti-mouse IgG antibody (Amersham; 1:100), Cy-3-conjugated anti-rat IgG antibody (Amersham, 1:3000), and Cy5-conjugated anti-human IgG antibody (Jackson Immuno Research Laboratories; 1:100 dilution), for 3-4 h at room temperature. After being washed with PBS, the samples were incubated with Hoechst 33342 (0.5 mg/ml) for 10 min, then incubated sequentially with 20, 40, 60, 80 and 90% of a glycerol-PBS mixture containing 2.5% 1,4-diazabicyclo-2,2,2-octane (DABCO), mounted in 95% glycerol containing 1mg/ml para-phenylene diamine as an anti-fading reagent, and observed with a fluorescence microscope system.
The details of the microscope system have been described previously (Hiraoka et al., 1991; Haraguchi et al., 1999) . In brief, fluorescence microscopic images were obtained with an Olympus microscope (IMT-2) using an oil immersion objective lens (SPlanApo 60, NA=1.4) and high-selectivity filters for Hoechst 33342, fluorescein, Texas Red and Cy-5 (Chroma Technology). Serial optical section image data (15-30 focal planes at 0.5 mm intervals) for DNA, topoisomerase II, alpha-tubulin or centromeres were collected on a Peltier-cooled charge-coupled device (Photometrics), and computationally processed by three-dimensional deconvolution method (Agard et al., 1989) 
Results
Anti-PS1212 antibody reacts with a specific phosphopeptide used as the antigen
To examine whether phosphorylation of topoisomerase II= modulates its function during the cell cycle, we have made antibodies against various phosphopeptides in topoisomerase II= (Ishida et al., 1996) . Here we examined an ansntibody raised against the oligopeptide which corresponds to the residues 1204-1219 in human topoisomerase II= containing PS1212. The specificity of the anti-PS1212 antibody was tested using a variety of phosphopeptides or nonphosphopeptides: the anti-PS1212 antibody reacted only with the phosphopeptide PS1212 used as an antigen, but not with the non-phosphorylated oligopeptide S1212 (Fig.1A) . Another monoclonal antibody against phosphorylated threonine-1342 (PT1342) recognized only the phospho-peptide PT1342 but not the other phosphopeptides PS29, PT949, PS1161 or PS1212 ( Fig. 1A ; see Materials and Methods).
Anti-PS1212 antibody recognizes human topoisomerase II= = = =
To test whether the anti-PS1212 antibody recognizes topoisomerase II=, HeLa cell extracts from non-synchronized and mitotic cells were prepared, subjected to electrophoresis, blotted, and analyzed by the anti-PS1212 antibody or several other antibodies against topoisomerase II (Fig. 1B) . As shown in Fig. 1B , the antibody against overall topoisomerase II= (1C5) recognized the 170 kDa protein in both non-synchronized and mitotic cells; the anti-PT1342 antibody also reacted with the 170 kDa in non-synchronized and mitotic cell extracts. In contrast with these antibodies, the anti-PS1212 antibody reacted with the 170 kDa protein in mitotic cell extracts, but only weakly reacted with the protein in non-synchronized cells (Fig. 1B) . To confirm that the 170 kDa protein recognized by the anti-PS1212 antibody is topoisomerase II=, the proteins of mitotic cells were first immunoprecipitated with anti-topoisomerase II= antibody 1C5, and the resulting immunoprecipitated materials were then probed with the anti-PS1212 antibody. The anti- PS1212 antibody recognized the anti-topoisomerase II= immunoprecipitates as a single band of 170 kDa (Fig. 1C) . In addition, the 170 kDa band detected by anti-topoisomerase II= was reduced by addition of the PS1212 peptide, but not by other phosphorylated peptides (data not shown). These results indicate that the anti-PS1212 antibody is highly specific to topoisomerase II= phosphorylated at serine1212.
Phosphorylation of topoisomerase II in the cell cycle
The phosphorylation of topoisomerase II= at serine1212 was examined in synchronized cells using the anti-PS1212 antibody. Since we found that the anti-PS1212 antibody recognized topoisomerase II= in mitotic cells more strongly than those in non-synchronized cells (Fig. 1) , we first synchronized cells in the M phase with TN-16, an inhibitor of microtubule formation , and these cells were allowed to progress to the G1 phase at 90 min after release from the M phase block. The amount of serine1212-phophorylated topoisomerase II= was significantly reduced following progression to the G1 phase ( Fig. 2A) . Next, we synchronized cells at the early S phase with a double thymidine block, then released to the G2/M phase. The cell cycle stage of the cells was estimated by mitotic index or flow cytometry: mitotic index showed that mitotic cells reached the peak of 25% at 8h after release of the block (Fig. 2B , upper panel); flow cytometry showed that the population of cells in G2/M phase reached the maximum of about 80% at 6 h after release of the block, and then decreased (data not shown), showing that cells were mostly in G2 at 6 h, and in mitosis at 8 h. In these synchronized cell populations, phosphorylation of topoisomerase II= at serine1212 was not detected at the S phase, increased slightly at 6 h, occurred at a high level at 8 h, and then decreased (Fig. 2B, lower  panel) . These results show that phosphorylation of topoisomerase II= at serine1212 occurs mainly in the M phase.
Localization of the phosphorylated topoisomerase II= = = = in HeLa cells
We first examined the subcellular localization of overall topoisomerase II= using an antibody 4E12 which recognizes topoisomerase II= regardless of its phosphorylation state; DNA and centromeres were stained with Hoechst 33342 and human autoimmune antiserum, respectively (Fig. 3) . We also examined the subcellular localization of the threonine1342-phosphorylated topoisomerase II (Fig. 4) . Localization of overall topoisomerase II= and the threonine1342-phosphorylated topoisomerase II= exhibited basically the same distribution pattern at any cell cycle stage. In interphase, the whole nuclear region was stained, with no obvious localization at the centromeres (Figs. 3A,  4A) ; in prophase, topoisomerase II= was detected along the axis of chromosome arms which resembles a mitotic chromosome scaffold, with some enrichment at the centromeres (Figs. 3B, 4B ). Concentration of topoisomerase II= at the centromeres became prominent in prometaphase to metaphase (Figs. 3C, 3D, 4C, 4D) , and then relocated to the Fig. 2 . Phosphorylation of topoisomerase IIa at serine1212 in M phase. Cells were synchronized at the M phase by TN-16 (A) and early S phase by double thymidine block (B), respectively, and allowed to start the cell cycle as described in Materials and Methods. Extracts were prepared from the cells and analyzed by immunoblotting with anti-PS1212 antibody. (A) After release from the M phase block, cells traversed into G1 phase after 2 h. (B) Mitotic cells were counted under a microscope after they were swollen in 75 mM KCl, fixed with methanol-acetic acid (3:1) and stained with Giemsa solution. Fig. 3 . Localization of DNA topoisomerase IIa during the cell cycle. Triple wavelength fluorescence staining was performed in methanol-fixed HeLa cells for DNA (left), topoisomerase IIa using the 4E12 antibody (middle), and centromeres (right), and a series of three dimensional image data at 0.5 mm focus intervals was processed as described in Materials and Methods. The subcellular localization of overall DNA topoisomerase IIa was compared with the position of centromeres in interphase (A), prophase (B), prometaphase (C), metaphase (D), anaphase (E) and telophase (F) cells. Scale bar represents 10 mm. Fig. 4 . Localization of DNA topoisomerase IIa phosphorylated at threonine1342 during the cell cycle. Triple wavelength fluorescence staining was performed in methanol-fixed HeLa cells for DNA (left), topoisomerase IIa using the anti-PT1342 antibody (middle), and centromeres (right), and a series of three dimensional image data at 0.5 mm focus intervals was processed as described in Materials and Methods. The subcellular localization of threonine 1342-phosphorylated DNA topoisomerase IIa was compared with the position of centromeres in interphase (A), prophase (B), prometaphase (C), metaphase (D), anaphase (E) and telophase (F) cells. Scale bar represents 10 mm. chromosome scaffolds in anaphase to telophase (Figs. 3E, 3F, 4E, 4F) .
Next, the subcellular localization of topoisomerase II= phosphorylated at serine1212 was examined (Fig. 5) . Anti-PS1212 antibody did not stain the interphase nucleus (Fig.  5A ), but did stain the chromosomal region seen as dots in the prophase, with some of the dots obviously having been colocalized with centromeres (Figs. 5B, 5C ). Intriguingly, most of these dots were located at the centromeres in the metaphase (Fig. 5D) . In anaphase, anti-PS1212 antibody stained the chromosome arms (Fig. 5E ), but this staining was no longer observed in late telophase (Figs. 5F, 5G) . Thus, the subcellular location of topoisomerase II= phosphorylated at serine1212 differs from that of overall topoisomerase II=.
To address the relationship between the centromere localization of serine1212-phosphorylated topoisomerase II= and its enzymatic activity, cells were treated with ICRF-193, a catalytic inhibitor of topoisomerase II (Ishida et al., 1991; Roca et al., 1994) . When HeLa cells are incubated in the presence of ICRF-193, the cells stayed in metaphase for about 6 h, whereas metaphase continues for about 30 min in the absence of ICRF-193; in those cells, chromosomes exhibit aberrant prometaphase-like morphology aligned at the middle of the mitotic spindle, and the mitotic spindle eventually disappears after the persistent metaphase without segregating chromosomes as observed in living cells (see Figs. 7 and 8 in Haraguchi et al., 1997) . We examined localization of the serine1212-phosphorylated topoisomerase II= on such prometaphase-like chromosomes in the cells that had been cultured for 5 h in the presence of . In these cells, the serine1212-phosphorylated topoisomerase II= was not localized at centromeres, whereas its association to centromeres was observed in the absence of (Fig. 6) . In contrast, centromere localization of the threonine-1342 phosphorylated topoisomerase II= was not affected by the presence of (Fig. 7) . Thus, localization of the serine1212-phosphorylated topoisomerase II to the centromeres depends on its enzymatic activity, whereas that of the threonine-1342 phosphorylated topoisomerase II= does not.
Discussion
We have described that serine1212 of topoisomerase II= is phosphorylated specifically in mitosis, and that the serine1212-phosphorylated topoisomerase II= is relocalized to the centromeres in a manner dependent on the enzyme activity. The centromere relocalization of serine1212-phosphorylated topoisomerase II= probably reflects the enzyme acting along the chromosome during formation of metaphase chromosomes.
Phosphorylation of mammalian topoisomerase II by various types of kinases has been reported (Wells et al., 1994; Ishida et al., 1996) . Several in vivo phosphorylation sites of toposomerase II= was deter- mined, such as serine-1524, serine-1376 and serine-1353 which contain the casein kinase II or cdc2 kinase consensus motif (Wells et al., 1994) . The neighboring peptides of serine1212 in topoisomerase II= has a cdc2 kinase recognition motif, and it has been shown that serine1212 in fact is phosphorylated by cdc2 kinase .
Serine1212 resides at the C-terminal region of topoisomerase II=, which varies significantly among species in contrast with the highly-conserved N-terminal region. The C-terminal region does not contain any catalytic functional domains such as an ATP binding site or DNA breakage and reunion (Caron and Wang, 1993) . However, deletion analysis in Drosophila, S. cerevisiae and human has shown that the C-terminal domain is involved in nuclear transport functions (Crenshaw and Hsieh, 1993; Caron et al., 1994; Mirski et al., 1997) . It is also speculated that the region is related to dimerization or to the regulation of enzyme activity (Caron and Wang, 1993) . Gene products which interact with the Cterminal region of topoisomerase II were isolated by a twohybrid cloning approach: Sgs1 (Watt et al., 1995; and Pat1 in S. cerevisiae, and TopBP1 in human (Yamane et al., 1997) . Thus, the C-terminal region of the enzyme may be involved in a regulatory function of enzyme activity or in interaction with other proteins; mitotic phosphorylation of topoisomerase II= at serine1212 may affect such interaction.
Topoisomerase II is known to be one of the major proteins associated with the chromosome scaffold or the nuclear matrix Gasser et al., 1986; . In addition to its localization to the chromosome scaffold, the association of topoisomerase II= with centromeres especially in metaphase has attracted attention (Taagepera et al., 1993; Rattner et al., 1996; Sumner, 1996) as the centromere is an essential region for chromosome segregation in metaphase (for a review, see Rieder and Salmon, 1998) . Topoisomerase II= is not located to the centromeres in interphase, but this association develops during prophase. It should be noted that phosphorylation of topoisomerase II= at serine1212 takes place in prophase, and serine1212-phosphorylated topoisomerase II= relocalizes to the centromere toward metaphase. In addition, ICRF-193 inhibits the centromere relocalization of serine1212-phosphorylated topoisomerase II=. Since ICRF-193 induces a closed clamp formation of topoisomerase II with DNA (Roca et al., 1994) , topoisomerase II can be expected to be retained at its location in the presence of this drug. Thus, mitosis-specific, serine1212 -phosphorylated topoisomerase II= may represent the enzyme in action resolving the topological constraint accumulated during metaphase chromosome condensation, and may have an essential role in topological resolution of sister chromatids in mitosis. Culture (RI) and by the Suzuken Memorial Foundation (RI); by grants from the Japan Science and Technology Corporation (Cooperative System for Supporting Priority Research, and CREST to YH) and the Japanese Ministry of Education, Science, Sports and Culture (TH and YH).
